National Institutes of Health

Metabolon develops metabolomics-based platforms and clinical diagnostic tests for early disease detection and precision medicine. It offers blood tests like QUANTOSE IR and QUANTOSE IGT, and Meta IMD for inherited metabolic disorders. The company serves various sectors including academia, biotech/pharmaceuticals, and precision medicine. It has strategic partnerships with major pharmaceutical companies and other industries.

North Carolina A&T State University is so many things to so many people, both in our state and around the country. North Carolina A&T State University is an HBCU. We are a top-flight research university, the largest historically black university (HBCU) in the country, the #1 producer of degrees awarded to African Americans in North Carolina and nationally recognized or our excellence in science, technology, mathematics and engineering (STEM) education. We are a diverse community, bound by intense pride and tradition, with fiercely loyal alumni who hold positions of importance and influence in companies and government agencies across the state, the country and the world. We are achievers, driven by a curious, limitless, fearless spirit that fuels discovery and innovation, resulting in 41 patents issued based on our research, as well as numerous spin-off and start-up companies. We are inclusive and welcoming, with students from many backgrounds and cultures, every part of our state, our nation and countries around the globe. We are passionate, driven by a desire to do more, be more and make more of a difference. Since we opened our doors in 1892, we have focused on giving every student the hands-on opportunities, core knowledge and global perspective that will lead them to make real and lasting change in their lives and the lives of others. At N.C. A&T, we have so much to be proud of, and you can learn more about those "Points of Pride" here. You can also use the links below to learn more about what makes N.C. A&T unique, from our leadership and history to our many rankings and recognitions.

Founded in 2006, Civatech Oncology is a medical device company based in Durham, North Carolina. It specializes in developing polymer-based devices for localized low-dose-rate radiation cancer treatment. The company's patented technology enables customizable devices tailored to specific tumor types, with its first product, the CivaString, FDA-cleared for treating solid tumors.

Dignify Therapeutics is a drug development company based in Raleigh, North Carolina. Founded in 2013, it focuses on restoring voluntary control of bladder and bowel functions for patients with spinal cord injury, spina bifida, multiple sclerosis, and other neurological conditions through novel pharmaceutical agents.

Wake Forest University, founded in 1834, is a respected private institution in the United States known for its strong academic reputation and rigorous liberal arts curriculum. As a non-profit organization, it is dedicated to personal education, fostering inquiry and exploration, and promoting service among its students. The university offers a range of undergraduate and graduate programs across various disciplines, emphasizing a holistic approach to education. Its investment portfolio reflects a commitment to financial stewardship, with a diverse allocation that includes absolute return strategies, fixed income, and public equity, among other asset classes. Wake Forest University continues to uphold its mission of providing a comprehensive educational experience that prepares students for meaningful contributions to society.

Wake Forest School of Medicine is an educational institution based in Winston Salem, North Carolina, founded in 1902. It specializes in biomedical research and offers primary care education and training, with students gaining hands-on experience with patients from their first week of medical school. The school also provides tertiary care, which is crucial for a research and teaching hospital. Wake Forest School of Medicine has a nationally recognized research program, attracting over $400 million in extramural funding annually. It educates nearly 1,900 students and fellows, including physicians, basic scientists, and allied clinical professionals.

Cell Microsystems, Inc. is a biotechnology company based in Research Triangle Park, North Carolina, that focuses on developing, manufacturing, and commercializing innovative tools for single-cell biology. Founded in 2010, the company is known for its proprietary CellRaft™ Technology, which allows for the efficient sorting and isolation of single cells under standard culture conditions, preserving their unperturbed phenotypes and high viability. This technology is complemented by an automated imaging platform, enabling real-time selection and tracking of individual cells throughout imaging, collection, and downstream analysis. By facilitating single-cell isolation from small and valuable samples, Cell Microsystems provides scalable solutions that make advanced cell separation technology accessible to laboratories, enhancing the capabilities of researchers in single-cell research and genomics.

Celldom, Inc. is a research tools company specializing in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing diversity within cell populations. Founded in 2016 and based in Durham, North Carolina, the company has developed the TrapTx Analyzer System, a cutting-edge platform that integrates phenotypic and genomic data at a large scale, capable of analyzing tens of thousands of cells in a single experiment. This technology is instrumental in identifying and characterizing rare cells that are crucial to understanding biological pathways and diseases. Celldom focuses on applying its innovative solutions primarily in the fields of oncology, immunology, and stem cell biology.

Founded in 2015, DILIsym Services develops predictive modeling software focused on drug-induced liver injury (DILI) for the pharmaceutical industry. Its flagship product, DILIsym, supports liver safety assessments during clinical drug development and allows users to perform in vitro to in vivo extrapolation, translate preclinical results to clinical trials, and evaluate patient variability's impact on hepatotoxicity predictions.

Perfusio is a medical device company founded in 2014 and headquartered in Greenville, North Carolina. It specializes in the development of advanced imaging technology that non-invasively visualizes blood flow and tissue perfusion in real time during surgical procedures. The company's flagship product, the Certes system, has received FDA clearance and provides surgeons with critical information about tissue integrity and blood flow. This technology allows for better-informed surgical decisions, helping to identify potential complications and improving patient outcomes. By enhancing real-time assessment capabilities, Perfusio's innovations aim to reduce procedural complications, minimize postoperative discomfort, and ultimately lower hospital costs.

Diabetic Health, Inc. is a medical technology company based in Research Triangle Park, North Carolina, specializing in the development of sensors and point-of-care devices aimed at detecting and monitoring critical medical conditions. Founded in 2009 and previously known as Clinical Sensors, Inc., the company focuses on harnessing the biological activity of nitric oxide to enhance the management of both acute and chronic diseases, including sepsis and diabetes. Its innovative devices are designed for use in intensive care units and hospital settings, allowing minimally trained clinical staff to monitor patients effectively. Diabetic Health has developed coatings to improve the performance of continuous glucose monitoring sensors and insulin infusion sets, utilizing nanoparticles that release nitric oxide to reduce inflammation and complications associated with diabetes. The company operates as a subsidiary of KNOW Bio, LLC, following its acquisition in December 2019.

Celldom, Inc. is a research tools company specializing in single-cell analysis technology aimed at enhancing research, drug discovery, and development by revealing diversity within cell populations. Founded in 2016 and based in Durham, North Carolina, the company has developed the TrapTx Analyzer System, a cutting-edge platform that integrates phenotypic and genomic data at a large scale, capable of analyzing tens of thousands of cells in a single experiment. This technology is instrumental in identifying and characterizing rare cells that are crucial to understanding biological pathways and diseases. Celldom focuses on applying its innovative solutions primarily in the fields of oncology, immunology, and stem cell biology.

NeuroCog Trials (NCT) is a cognition and clinical assessment services company devoted exclusively to applying rigorous standards for key endpoints in multi-site clinical trials. Founded in 2005, NeuroCog Trials is a privately held, certified woman-owned business, headquartered in Durham, North Carolina. There are currently 110 Durham based and 50+ international employees and local language experts.

Zenalux Biomedical is a biomedical diagnostics start-up located in Research Triangle Park, North Carolina. The company specializes in biophotonics and has established itself as a leader in this field through strong connections with Duke University. Zenalux is focused on simplifying optical spectroscopy for medical practitioners, enabling real-time, non-destructive diagnostics of biological tissue. Their innovative products translate ultraviolet-visible tissue spectra into quantified biological endpoints, allowing healthcare professionals to concentrate on the practical applications of this advanced technology in clinical settings. With a highly qualified management team possessing extensive executive experience, Zenalux aims to enhance diagnostic capabilities in the medical field.

BioMedomics is a medical diagnostics company specializing in point-of-care testing products. Established in 2006, it offers a range of diagnostic tools including tests for sickle cell disease, fungal infections, COVID-19, and vaginal infections.

Dignify Therapeutics is a drug development company based in Raleigh, North Carolina. Founded in 2013, it focuses on restoring voluntary control of bladder and bowel functions for patients with spinal cord injury, spina bifida, multiple sclerosis, and other neurological conditions through novel pharmaceutical agents.

TransTech Pharma, Inc., a clinical-stage pharmaceutical company, engages in the discovery, development, and commercialization of human therapeutics. The company engages in translating human proteins into medicines for the treatment of various human diseases. Its products include a pipeline of molecule clinical and pre-clinical drug candidates, including antagonists, fusion proteins, activators, inhibitors, agonists, smallpox anti-virals, and thrombosis for the treatment of cardiovascular disorders, central nervous system disorders, inflammatory and infectious diseases, diabetes, obesity, and cancer. TransTech Pharma, Inc. has strategic alliances with Novo Nordisk A/S, Pfizer, Boehringer Ingelheim, Merck, Siga Technologies, and Cephalon. The company was founded in 1998 and is based in High Point, North Carolina.

Chimerix, Inc. is a biopharmaceutical company based in Durham, North Carolina, focused on the development of innovative medicines for patients with cancer and serious viral infections. The company is advancing several clinical-stage programs, including dociparstat sodium (DSTAT), a glycosaminoglycan compound aimed at improving outcomes for patients with acute myeloid leukemia during chemotherapy. Another key candidate is brincidofovir (BCV), an antiviral drug being developed as a medical countermeasure for smallpox. Chimerix also leads the development of CMX001, a broad-spectrum antiviral agent targeting life-threatening double-stranded DNA viral infections, currently undergoing multiple clinical studies for use in immunocompromised patients. Additionally, CMX157, an antiviral compound with activity against HIV and hepatitis B, is in development, addressing challenges posed by existing therapies. The company collaborates with various organizations for research and commercialization, deriving revenue from licensing agreements and royalties. Founded in 2000, Chimerix is committed to transforming patient care through its advanced therapeutic candidates.